1
|
Desai N, Hunold T, Kaperak C, Wang W, Kavitt R. Pharmacologic causes of dysphagia. Dysphagia 2023. [DOI: 10.1016/b978-0-323-99865-9.00003-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
2
|
Han LQ, Wang CH, Cui TT, Liu F, Wang XD, Wang ZK, Li W. Comparison of the Therapeutic Effects of Iodine-125 Seed Implantation and Conventional Radiochemotherapy for Advanced Esophageal Cancer. Cancer Control 2022; 29:10732748221142946. [PMID: 36542559 PMCID: PMC9793016 DOI: 10.1177/10732748221142946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The purpose of this study was to explore the feasibility, safety and efficacy of iodine-125 seed implantation in the treatment of dysphagia of advanced esophageal cancer. METHODS We retrospectively analyzed patients with advanced esophageal cancer who underwent EUS-guided iodine-125 seed implantation or conventional chemoradiotherapy in our hospital. The propensity score match was used to reduce the baseline differences. RESULTS A total of 127 patients were enrolled, 17 patients received EUS-guided iodine 125 seed implantation (Group A), 31 patients received radiotherapy (Group B), 38 patients received chemotherapy (Group C) and 41 patients received chemotherapy combined with radiotherapy (Group D). At half month postoperatively, the dysphagia remission rate in Group A (100%) was better than that in Groups B (39.3%), C (20%), D (15.8%), respectively, in the original cohort (P < 0.01); At 1 month postoperatively, the dysphagia remission rate in Group A (86.7%) was better than that in Group B (57.1%) (P > 0.05), Group C (25.7%) (P < 0.05) and Group D (34.2%) (P < 0.05), respectively, in the original cohort. There was no statistically significant difference in median overall survival (OS) between Group A (16 months) and Group B (37 months) (P = 0.149), and between Group A (16months) and Group C (16 months) (P = 0.918) in the original cohort. The mean OS of Group D (54 months) was better than that of Group A (20 months) in the original cohort (P = 0.031). The incidences of grade ≥2 myelosuppression in Groups B, C, and D were 12.9%, 28.9%, and 43.9%, respectively; the incidence of grade ≥2 gastrointestinal adverse events in Groups B, C, and D were 12.9%, 15.8%, 12.2%, respectively. No serious adverse events were found in Group A. The radiation dose around the patient was reduced to a safe range after the distance from the implantation site was more than 1 m (4.2 ± 2.6 μSv/h) or with lead clothing (0.1 ± 0.07 μSv/h). CONCLUSIONS Compared with conventional radiotherapy or chemotherapy alone, iodine-125 seed implantation might improve dysphagia more quickly and safely, further clinical data is needed to verify whether it could effectively prolong the OS of patients.
Collapse
Affiliation(s)
- Lian-Qiang Han
- School of Medicine, Nankai University, Tianjin, China,Medical School of Chinese People’s Liberation Army (PLA),
Beijing, China,Department of Gastroenterology and
Hepatology, The First Medical Center, Chinese PLA General
Hospital, Beijing, China
| | - Chen-Huan Wang
- Department of Gastroenterology and
Hepatology, The First Medical Center, Chinese PLA General
Hospital, Beijing, China
| | - Ting-Ting Cui
- Department of Gastroenterology, Air
Force Medical Center, Air Force Medical University, Beijing, China
| | - Fang Liu
- Department of Gastroenterology and
Hepatology, The First Medical Center, Chinese PLA General
Hospital, Beijing, China
| | - Xiang-Dong Wang
- Department of Gastroenterology and
Hepatology, The First Medical Center, Chinese PLA General
Hospital, Beijing, China
| | - Zi-Kai Wang
- Department of Gastroenterology and
Hepatology, The First Medical Center, Chinese PLA General
Hospital, Beijing, China
| | - Wen Li
- School of Medicine, Nankai University, Tianjin, China,Medical School of Chinese People’s Liberation Army (PLA),
Beijing, China,Department of Gastroenterology and
Hepatology, The First Medical Center, Chinese PLA General
Hospital, Beijing, China,Wen Li, MD, PhD, School of Medicine, Nankai
University, No. 94 Weijin Road, Tianjin, 300071, China.
| |
Collapse
|